Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells

Vascular Pharmacology

Volumn 50, Issue 1-2, 2009, Pages 45-50

  Star, Gregory P ^a   Giovinazzo, Michele ^a   Langleben, David ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bone morphogenic protein; Endothelin 1; Microvascular endothelium; Pulmonary arterial hypertension; Transforming growth factor beta

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CELL PROTEIN; ENDOTHELIN 1; OSTEOGENIC PROTEIN 1; SMAD1 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; LUNG ENDOTHELIUM; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 7; CELLS, CULTURED; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; LUNG; MICROCIRCULATION; PHOSPHORYLATION; SMAD1 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 57349146222     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.09.001     Document Type: Article

References (34)

1. Archer S.L., Djaballah K., Humbert M., Weir E.K., Fartoukh M., Dall'ava-Santucci J., Mercier J.C., Simonneau G., and Dinh-Xuan A.T. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 158 (1998) 1061-1067
2. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., Naeije R., and Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
3. Castanares C., Redondo-Horcajo M., Magan-Marchal N., Ten Dijke P., Lamas S., and Rodriguez-Pascual F. Signalling by ALK5 mediates TGFb-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci 120 (2007) 1256-1266
4. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., and Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
5. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G., Kalachikov S., Cayanis E., Fisher S.G., Barst R.J., Hodge S.E., and Knowles J.A. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
6. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with primary pulmonary hypertension. N Engl J Med 333 (1995) 214-221
7. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., and Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
8. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F., and Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 13S-24S
9. Kitten A.M., and Andrews C.J. Endothelin-1 expression in long-term cultures of fetal rat calvarial osteoblasts: regulation by BMP-7. J Cell Physiol 187 (2001) 218-225
10. Kiyono M., and Shibuya M. Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4. Oncogene 25 (2006) 7131-7137
11. Kurihara H., Yoshizumi M., Sugiyama T., Takaku F., Yanagisawa M., Masaki T., Hamaoki M., Kato H., and Yazaki Y. Tranforming growth factor-stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 159 (1989) 1435-1440
12. Lane K.B., Machado R.D., Pauciulo M.W., Thompson J.R., Phillips J.A., Loyd J.E., Nichols W.C., and Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26 (2000) 81-84
13. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 28 (2007) 117-125
14. Langleben D., Barst R.J., Badesch D., Groves B.M., Tapson V.F., Murali S., Bourge R.C., Ettinger N., Shalit E., Clayton L.M., Jobsis M.M., Blackburn S.D., Crow J.W., Stewart D.J., and Long W. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 99 (1999) 3266-3271
15. Langleben D., Dupuis J., Langleben I., Hirsch A.M., Baron M., Senecal J.L., and Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129 (2006) 689-695
16. Lee S.D., Lee D.S., Chun Y.G., Paik S.H., Kim W.S., Kim D.S., Kim W.D., Tuder R.M., and Voelkel N.F. Transforming growth factor-1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. Pulm Pharmacol Ther 13 (2000) 257-265
17. Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V., Wheeler L., Phillips J.A., Newman J., Williams D., Galie N., Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P., Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E., Trembath R.C., and Nichols W.C. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68 (2001) 92-102
18. Michael J.R., and Markewitz B.A. Endothelins and the lung. Am Rev Respir Dis 154 (1996) 555-581
19. Miyazono K., Maeda S., and Imamura T. BMP receptor signalling: transcriptional targets, regulation of signals, and signalling cross-talk. Cytokine Growth Factor Rev 16 (2005) 251-263
20. Morrell N.W. Pulmonary hypertension due to BMPR2 mutations. Proc Am Thorac Soc 3 (2006) 680-686
21. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K., and Trembath R.C. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenic proteins. Circulation 104 (2001) 790-795
22. Newman J.H., Phillips J.A., and Loyd J.E. Narrative review: the enigma of pulmonary arterial hypertension: New insights from genetic studies. Ann Intern Med 148 (2008) 278-283
23. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., and Knaus P. The mode of bone morphogenic protein (BMP) receptor oligomerization determines different BMP-2 signalling pathways. J Biol Chem 277 (2002) 5330-5338
24. Perez del Villar C., Alonso C.J.G., Feldstein C.A., Juncos L.A., and Romero J.C. Role of endothelin in the pathogenesis of hypertension. Mayo Clin Proc 80 (2005) 84-96
25. Pietra G.G., Capron F., Stewart S., Leone O., Humbert M., Robbins I.M., Reid L.M., and Tuder R.M. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004) 25S-32S
26. Prins B., Hu R.M., Nazario B., Pedram A., Frank J.L., Weber M., and Levin E.R. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 269 (1994) 11938-11944
27. Rodriguez-Pascual F., Reimunde F.M., Redondo-Horcajo M., and Lamas S. Transforming growth factor-induces endothelin-1 expression through activation of the Smad signalling pathway. J Cardiovasc Pharmacol 44 (2004) S39-S42
28. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
29. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Dominghetti G., Gibbs S., Lebrec D., Speich R., Beghetti M., Rich S., and Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
30. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
31. Teichert-Kuliszewska K., Kutryk M.J.B., Kuliszewski M.A., Karoubi G., Courtman D.W., Zucco L., Granton J., and Stewart D.J. Bone morphogenic protein receptor-2 signalling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 98 (2006) 209-217
32. Trembath R.C., Thomson J.R., Machado R.J., Morgan N.V., Atkinson C., Winship I., Simonneau G., Galie N., Loyd J.E., Humbert M., Nichols W.C., and Morrell N.W. Clinical and molecular genetic features of pulmonary hypertension in patients with herediatary hemorrhagic telangiectasia. N Engl J Med 345 (2001) 325-334
33. Tuder R.M., Cool C.D., Geraci M.W., Wang J., Abman S.H., Wright L., Badesch D., and Voelkel N.F. Prostacycline synthase gene expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Resp Crit Care Med 159 (1999) 1925-1932
34. Yamashita H., Ten Dijke P., Heldin C.-H., and Miyazono K. Bone morphogenic protein receptors. Bone 19 (1996) 569-574